BWV - Blue Water Vaccines, Inc. Stock Price, Fair Value and News

0.16USD-0.01 (-5.88%)Market Closed

Market Summary

USD0.16-0.01

Market Closed

-5.88%

BWV Stock Price

View Fullscreen

BWV RSI Chart

BWV Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.2

Price/Free Cashflow

-0.26

BWV Price/Earnings (Trailing)

BWV Profitability

Return on Equity

326.25%

Return on Assets

-20.88%

Free Cashflow Yield

-380.25%

BWV Fundamentals

BWV Earnings

Earnings (TTM)

-18.3M

Earnings Growth (Yr)

-38.28%

Earnings Growth (Qtr)

22.12%

Breaking Down BWV Revenue

Last 7 days

-5.9%

Last 30 days

-5.9%

Last 90 days

-51.5%

Trailing 12 Months

-87.1%

How does BWV drawdown profile look like?

BWV Financial Health

Current Ratio

0.34

BWV Investor Care

Shares Dilution (1Y)

40.61%

Diluted EPS (TTM)

-2.08

Tracking the Latest Insider Buys and Sells of Blue Water Vaccines, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 31, 2023	ramdeen timothy r.	acquired	-	-	6,360	-
May 31, 2023	jeremic vuk	acquired	-	-	6,360	-
May 31, 2023	tarsh simon	acquired	-	-	6,360	-
May 31, 2023	sapirstein james	acquired	-	-	6,360	-
May 09, 2023	henderson erin	acquired	-	-	150,000	chief business officer
May 09, 2023	hernandez joseph	acquired	-	-	150,000	ceo
May 09, 2023	garfield jon	acquired	-	-	100,000	chief financial officer
Apr 10, 2023	cincinnati cornerstone investors bwv i, llc	sold	-	-	-1,200,000	-
Nov 17, 2022	cincinnati cornerstone investors bwv i, llc	sold	-	-	-750,000	-
Aug 25, 2022	cincinnati cornerstone investors bwv i, llc	sold	-	-	-500,000	-

Which funds bought or sold BWV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Bogart Wealth, LLC	unchanged	-	-1.00	2.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-5,133	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-4,233	14,814	-%
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	-26.00	92.00	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-62.39	-85,455	14,556	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-45.47	-13,000	3,000	-%
Feb 16, 2024	O'Dell Group, LLC	new	-	23.00	23.00	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-12,009	7,582	-%

Are Funds Buying or Selling BWV?

Are funds buying BWV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BWV

No. of Funds

Unveiling Blue Water Vaccines, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 26, 2024	american financial group inc	7.7%	1,440,927	SC 13G/A
Jan 02, 2024	sabby management, llc	4.99%	930,905	SC 13G/A
Dec 28, 2023	altos venture ag	5.0%	1,103,403	SC 13G
Jun 29, 2023	cincinnati cornerstone investors bwv i, llc	0%	0	SC 13D
Apr 13, 2023	cincinnati cornerstone investors bwv i, llc	7%	1,161,201	SC 13D
Feb 14, 2023	hernandez joseph	18.43%	2,850,351	SC 13G
Jan 31, 2023	american financial group inc	6.08%	940,762	SC 13G
Jan 04, 2023	sabby management, llc	7.82%	1,210,686	SC 13G
Nov 21, 2022	cincinnati cornerstone investors bwv i, llc	15%	2,361,201	SC 13D
Aug 29, 2022	cincinnati cornerstone investors bwv i, llc	22.9%	3,111,201	SC 13D

Recent SEC filings of Blue Water Vaccines, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	S-1/A	Initial Public Offering
Apr 11, 2024	10-K	Annual Report
Apr 08, 2024	8-K	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 13, 2024	8-K/A	Current Report
Feb 27, 2024	8-K/A	Current Report
Feb 21, 2024	4	Insider Trading
Feb 16, 2024	3	Insider Trading
Feb 16, 2024	3	Insider Trading

Peers (Alternatives to Blue Water Vaccines, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Blue Water Vaccines, Inc. News

Latest updates

Blue Water Vaccines, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	213.9%	87,518	27,882	29,748	22,502	26,310	30,161	23,634	19,335	3,085	4,812
Current Assets	-38.8%	5,838	9,541	11,405	22,472	26,258	30,052	23,514	19,103	3,073	4,596
Cash Equivalents	-40.5%	4,554	7,654	9,223	21,256	25,753	29,137	22,242	18,609	1,928	4,309
Inventory	-74.3%	364	1,419	1,172	-	-	-	-	-	-	-
Net PPE	385.1%	61.00	13.00	14.00	14.00	14.00	16.00	18.00	15.00	12.00	16.00
Liabilities	-	21,877	-	16,672	2,809	3,922	3,351	2,780	2,209	1,638	-
Current Liabilities	-2.6%	17,190	17,645	12,134	2,809	3,922	4,431	3,059	2,801	1,638	69.00
Shareholder's Equity	-154.7%	-5,602	10,236	13,076	19,693	22,388	25,730	20,575	16,534	1,447	4,734
Retained Earnings	-64.9%	-56,786	-34,435	-29,088	-22,223	-19,376	-16,158	-12,291	-8,027	-5,956	-2,539
Additional Paid-In Capital	9.1%	49,429	45,297	42,790	42,517	42,331	41,888	32,867	24,561	7,403	7,273
Shares Outstanding	25.3%	22,325	17,819	16,413	15,879	15,265	14,338	9,227	6,339	3,200	3,200
Float	-	-	-	13,000	-	-	-	9,800	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-41.8%	-4,311	-3,040	-1,782	-4,446	-2,823	-1,814	-3,174	-886	-674	-730	-382	-256	-
Share Based Compensation	-322.0%	-234	105	273	186	178	330	1,447	19.00	24.00	29.00	35.00	42.00	-
Cashflow From Investing	602.6%	1,216	173	-10,035	-1.82	22.00	-14.31	-11.98	-5.20	-	-	-	-	-
Cashflow From Financing	-100.0%	-	1,299	-214	-48.95	-582	8,724	6,819	17,572	-	-	-	-	-
Buy Backs	-	-	-	26.00	33.00	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BWV Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 58,465
Cost of revenue	1,185,630
Gross loss	(1,127,165)
Operating expenses
Selling, general and administrative	14,770,678	9,351,552
Research and development	1,949,406	4,129,688
Impairment of ENTADFI assets	14,687,346
Impairment of deposit on asset purchase agreement	3,500,000
Total operating expenses	34,907,430	13,481,240
Loss from operations	(36,034,595)	(13,481,240)
Other income (expense)
Loss on extinguishment of note payable	(490,000)
Interest expense	(671,625)
Change in fair value of subscription agreement liability	(134,100)
Change in fair value of contingent warrant liability	(91,967)	61,410
Total other income (expense)	(1,387,692)	61,410
Loss before income taxes	(37,422,287)	(13,419,830)
Income tax benefit	12,593
Net loss	(37,409,694)	(13,419,830)
Cumulative preferred stock dividends		96,359
Net loss attributable to common stockholders	$ (37,409,694)	$ (13,516,189)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (2.19)	$ (1.1)
Weighted average number of common shares outstanding, basic (in Shares)	17,111,374	12,271,449
Other comprehensive loss
Net loss	$ (37,409,694)	$ (13,419,830)
Foreign currency translation	2,374,957
Change in pension benefit obligation	5,963
Total comprehensive loss attributable to common stockholders	$ (35,028,774)	$ (13,419,830)

BWV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 4,554,335	$ 25,752,659
Accounts receivable, net	149,731
Inventories	364,052
Prepaid expenses and other current assets	770,153	469,232
Total current assets	5,838,271	26,257,741
Prepaid expenses, long-term	17,423	38,617
Property and equipment, net	60,654	14,089
Deferred offering costs	366,113
Operating right of use asset	148,542
Intangible assets, net	25,410,887
Goodwill	55,676,142
Total assets	87,518,032	26,310,447
Current liabilities
Accounts payable	5,295,114	1,499,296
Accrued expenses	2,199,867	2,409,128
Notes payable, net of debt discount of $381,627	9,618,373
Operating lease liability, current	74,252
Contingent warrant liability	2,641	14,021
Total current liabilities	17,190,247	3,922,445
Note payable	118,857
Subscription agreement liability	864,000
Pension benefit obligation	556,296
Operating lease liability, net of current portion	74,290
Deferred tax liability, net	3,073,781
Total liabilities	21,877,471	3,922,445
Commitments and Contingencies (see Note 10)
Series B Convertible Redeemable Preferred stock, $0.00001 par value, 2,700,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 2,696,729 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively	64,236,085
Stockholders’ equity (deficit)
Series A Convertible Preferred stock, $0.00001 par value, 10,000 and 0 shares authorized at December 31, 2023 and 2022, respectively; 3,000 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively; Liquidation preference of $3,000,000 and $0 at December 31, 2023 and 2022, respectively.
Common stock, $0.00001 par value, 250,000,000 shares authorized at December 31, 2023 and 2022; 22,841,975 and 15,724,957 shares issued at December 31, 2023 and 2022, respectively; 22,324,576 and 15,265,228 shares outstanding at December 31, 2023 and 2022, respectively	228	157
Additional paid-in-capital	49,428,809	42,331,155
Treasury stock, at cost; 517,399 and 459,729 shares of common stock at December 31, 2023 and 2022, respectively	(625,791)	(566,810)
Accumulated deficit	(56,786,194)	(19,376,500)
Accumulated other comprehensive income	2,380,920
Total Onconetix stockholders’ equity (deficit)	(5,602,028)	22,388,002
Non-controlling interest	7,006,504
Total stockholders’ equity	1,404,476	22,388,002
Total liabilities, convertible redeemable preferred stock, and stockholders’ equity (deficit)	87,518,032	26,310,447
Related Party
Current assets
Receivable from related parties, net		$ 35,850

About Blue Water Vaccines, Inc.

Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

WEBSITE	bwbioinc.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Blue Water Vaccines, Inc. Frequently Asked Questions

What is the ticker symbol for Blue Water Vaccines, Inc.? What does BWV stand for in stocks?

BWV is the stock ticker symbol of Blue Water Vaccines, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Blue Water Vaccines, Inc. (BWV)?

As of Sun Mar 31 2024, market cap of Blue Water Vaccines, Inc. is 3.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BWV stock?

You can check BWV's fair value in chart for subscribers.

What is the fair value of BWV stock?

You can check BWV's fair value in chart for subscribers. The fair value of Blue Water Vaccines, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Blue Water Vaccines, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BWV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Blue Water Vaccines, Inc. a good stock to buy?

The fair value guage provides a quick view whether BWV is over valued or under valued. Whether Blue Water Vaccines, Inc. is cheap or expensive depends on the assumptions which impact Blue Water Vaccines, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BWV.